Trial Profile
Randomized, Double Blind Evaluation of Late Boost Strategies for HIV-uninfected Participants in the HIV Vaccine Efficacy Trial RV 144: "Aventis Pasteur Live Recombinant ALVAC-HIV (vCP1521) Priming With VaxGen gp120 B/E (AIDSVAX B/E) Boosting in HIV-uninfected Thai Adults"
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2022
Price :
$35
*
At a glance
- Drugs HIV gp120 vaccine (Primary) ; HIV vaccine vCP1521 (Primary)
- Indications HIV infections
- Focus Adverse reactions; Pharmacodynamics
- 02 Nov 2020 Planned End Date changed from 1 Dec 2020 to 1 Jul 2021.
- 02 Nov 2020 Planned primary completion date changed from 1 Jul 2020 to 1 Jul 2021.
- 16 Sep 2019 Planned End Date changed from 1 Dec 2019 to 1 Dec 2020.